Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

被引：74
|
作者：
Saciuk, Yaki [1 ]
Kertes, Jennifer [1 ]
Stein, Naama Shamir [1 ]
Zohar, Anat Ekka [1 ]
机构：
[1] Maccabi HealthCare Serv, Div Data & Digital Hlth, Tel Aviv, Israel
来源：
JOURNAL OF INFECTIOUS DISEASES | 2022年 / 225卷 / 01期
关键词：
vaccine effectiveness; COVID-19; SARS-CoV-2; Pfizer-BioNTech vaccine; mRNA BNT162b2; COVID-19; VACCINE; ISRAEL; IMPACT;
D O I：
10.1093/infdis/jiab556
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January-February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August-October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%-93.2%) and adjusted VE was 89.1% (95% CI, 87.5%-90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.
引用
收藏
页码：30 / 33
页数：4
相关论文
共 50 条
  • [31] Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
    Magen, Ori
    Waxman, Jacob G.
    Makov-Assif, Maya
    Vered, Roni
    Dicker, Dror
    Hernan, Miguel A.
    Lipsitch, Marc
    Reis, Ben Y.
    Balicer, Ran D.
    Dagan, Noa
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (17): : 1603 - 1614
  • [32] Acute myocarditis after a third dose of the BNT162b2 COVID-19 vaccine
    Fosch, Xavier
    Serra, Julia
    Torres, Pedro L.
    Preda, Luminita
    Gonzalez, Rosa
    Mojer, Francisca
    REVISTA ESPANOLA DE CARDIOLOGIA, 2022, 75 (07): : 614 - 616
  • [33] Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
    Peled, Yael
    Ram, Eilon
    Lavee, Jacob
    Segev, Amit
    Matezki, Shlomi
    Wieder-Finesod, Anat
    Halperin, Rebecca
    Mandelboim, Michal
    Indenbaum, Victoria
    Levy, Itzchak
    Sternik, Leonid
    Raanani, Ehud
    Afek, Arnon
    Kreiss, Yitshak
    Lustig, Yaniv
    Rahav, Galia
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (02): : 148 - 157
  • [34] Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
    Terashima, Takeshi
    IDCASES, 2021, 26
  • [35] Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
    Nunez Lopez, Concepcion
    Manuel Gonzalez de Abreu, Juan
    Perez-Blanco, Veronica
    de Miguel Buckley, Rosa
    Romero Gomez, Maria Pilar
    Diaz-Menendez, Marta
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2023, 41 (01): : 33 - 35
  • [36] Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF
    Karampitsakos, T.
    Dimeas, I
    Tsiri, P.
    Sotiropoulou, V
    Tomos, I
    Papanikolaou, I
    Katsaras, M.
    Kirgou, P.
    Daniil, Z.
    Gourgoulianis, K.
    Papalexatos, D.
    Sampsonas, F.
    Manali, E.
    Papiris, S.
    Bouros, D.
    Tzouvelekis, A.
    Papaioannoui, o
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [37] Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses
    Chang, Amy
    Chiang, Teresa PY.
    Kim, Jake D.
    Mitchell, Jonathan
    Alejo, Jennifer L.
    Jefferis, Alexa A.
    Avery, Robin K.
    Tobian, Aaron A. R.
    Levan, Macey L.
    Warren, Daniel S.
    Garonzik-Wang, Jacqueline M.
    Massie, Allan B.
    Segev, Dorry L.
    Werbel, William A.
    CLINICAL TRANSPLANTATION, 2022, 36 (08)
  • [38] Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers
    Lee, Dong Yeop
    Kang, Dong Yoon
    Kim, Eunjung
    Lee, Se-joo
    Baek, Ji Hyeon
    Lee, Jin-Soo
    Park, Mi Youn
    Im, Jae Hyoung
    MEDICINE, 2023, 102 (11) : E33236
  • [39] Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
    Caocci, Giovanni
    Mulas, Olga
    Mantovani, Daniela
    Costa, Alessandro
    Galizia, Andrea
    Barabino, Luca
    Greco, Marianna
    Murru, Roberta
    La Nasa, Giorgio
    BLOOD, 2021, 138
  • [40] BNT162b2 mRNA vaccine in transfusion dependent thalassemia patients
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    TRANSFUSION MEDICINE, 2024, 34 (04) : 329 - 329
12345